MARKET

VTGN

VTGN

Vistagen Therapeutics Inc
NASDAQ
4.240
-1.000
-19.08%
Opening 12:47 10/02 EDT
OPEN
4.890
PREV CLOSE
5.24
HIGH
4.890
LOW
4.000
VOLUME
1.41M
TURNOVER
0
52 WEEK HIGH
24.71
52 WEEK LOW
1.620
MARKET CAP
39.70M
P/E (TTM)
-0.6381
1D
5D
1M
3M
1Y
5Y
Vistagen prices $100M underwritten offering
Seeking Alpha · 13h ago
Vistagen Therapeutics Plans To Launch The Palisade-3 Trial In 1H Of 2024 And Palisade-4 In 2H Of 2024 - 8K
Benzinga · 14h ago
Weekly Report: what happened at VTGN last week (0925-0929)?
Weekly Report · 16h ago
Weekly Report: what happened at VTGN last week (0918-0922)?
Weekly Report · 09/25 09:00
Weekly Report: what happened at VTGN last week (0911-0915)?
Weekly Report · 09/18 09:00
Maxim Group Reaffirms Their Buy Rating on VistaGen Therapeutics (VTGN)
TipRanks · 09/13 20:05
Vistagen Announces Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
Benzinga · 09/12 12:33
10 Short Squeeze Stocks To Watch: Getty Images, Bitcoin Depot, Blue Apron Holdings And More
Benzinga · 09/11 14:52
More
About VTGN
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. It is advancing therapeutics for treatment of anxiety, depression, and multiple CNS disorders. Its pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH15, PH80, and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines, which are administered as low-dose nasal sprays, are designed with a rapid-onset mechanism of action that activates chemosensory neurons in the nasal cavity and can impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. PH94B is a synthetic investigational pherine from the androstane family.

Webull offers kinds of Vistagen Therapeutics Inc stock information, including NASDAQ:VTGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTGN stock methods without spending real money on the virtual paper trading platform.